AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02060383 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: If previously normo-glycemic participants experienced increase in their fasting blood glucose and meeting the criteria for diabetes while on pasireotide, they started anti-diabetic treatment using metformin. If they continued to experience increase in their fasting blood glucose within the first 16 weeks, they were randomized in a 1:1 ratio to receive treatment with incretin based therapy or insulin for approximately 16 weeks. Metformin treatment was not required for the BL Insulin and OAD groups, within the non-randomized arm, but may have been prescribed at the discretion of the investigator.~Note: No OAD group within the non-randomized arm did not take metformin.
Study NCT01851278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone hexacetonide
Description: High dose means 40mg or 2ml of triamcinolone hexacetonide
Study NCT01851278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone hexacetonide
Description: Low dose means 20mg or 1 ml of triamcinolone hexacetonide
Study NCT03307434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Athletics Injury Prevention Program
Description: The Athletics Injury Prevention Program (AIPP) will be performed by experimental group twice a week. The AIPP is composed of 8 exercises including core stability, balance, pelvic stabilization, stretching and strengthening of the Achilles tendon and hamstrings.
Study NCT03307434 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: regular training
Description: The regular training will be performed by control group according to the standard practice.
Study NCT01388231 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT-Manualized Intervention
Description: Cognitive-behavioral therapy (CBT) for social phobia following the Clark and Wells (1995) model of social phobia.
Study NCT01388231 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT-Treatment as Usual
Description: Cognitive-behavioral therapy for social phobia following no specific model.
Study NCT02954146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connectd mobile application
Description: Connectd is a mobile application that collects and automatically analyzes input from patients with PTSD/TBI, as well as their families, for clinician review. The app will aggregate patient and family input on current issues, relationship stressors, and situational stressors to better focus (personalize) treatment as well as to more efficiently and accurately understand key factors and root causes. In addition, the app provides informational resources for veterans and family regarding treatment options and mental health supports.
Study NCT02954146 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Connectd mobile application
Description: Connectd is a mobile application that collects and automatically analyzes input from patients with PTSD/TBI, as well as their families, for clinician review. The app will aggregate patient and family input on current issues, relationship stressors, and situational stressors to better focus (personalize) treatment as well as to more efficiently and accurately understand key factors and root causes. In addition, the app provides informational resources for veterans and family regarding treatment options and mental health supports.
Study NCT01864187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The volunteers would receive a dosage of dexmedetomidine by 1μg/kg.
Study NCT00000387 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management therapy
Description: Behavioral
Study NCT00000387 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-management therapy
Description: Behavioral
Study NCT00000387 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management therapy
Study NCT00000387 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-management therapy
Study NCT02991508 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02991508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adrecizumab
Study NCT00121836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m² PO BID on Days 1-15 of each 3-week cycle
Study NCT00121836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg IV on Day 1 of each 3-week cycle
Study NCT03248583 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Default option
Description: The default option is a behavioral economics construct that refers to the option a consumer selects if no active choice is made (e.g. opt-out 401K plans, which significantly increase enrollment, compared to active sign up).~Participants in the default condition were presented with a pre-filled online shopping cart containing a combination of groceries that meet macro- and micronutrient requirements for their gender and age, and told that they are free to delete, add, and exchange any item they wish to finalize their selections.
Study NCT03248583 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Participants in the psychoeducation condition were instructed to read a brief psychoeducational brochure adapted from materials currently utilized by the New York State Office of Temporary and Disability Assistance (Eat Smart New York).
Study NCT03248583 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Incentive
Description: Participants in the incentive condition were informed that they will receive a gift card to a major retailer of their choice if they select groceries that meet recommended nutritional guidelines for macro- and micronutrient requirements. Participants were given examples of macro- and micronutrients to ensure that the instructions were clear.
Study NCT00345189 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CNF2024
Description: CNF2024 capsules administered orally following 2 schedules:~* starting dose of 25 mg, twice a week for 3 weeks out of a 4-week course (Schedule 1) or~* starting dose of 600 mg twice a week for 4 weeks out of a 4-week course (without drug holidays; Schedule 2).~Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Dose escalation proceeds according to the predetermined scheme until the stopping dose is reached due to a dose limiting toxicity (DLT) occurring during the first 4-week course of treatment.
Study NCT01733342 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Celsite chemoport implantation
Description: Celsite chemoport implantation was done under local anesthesia, at anterior chest wall, under ultrasound guidance
Study NCT01733342 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: local anesthesia
Description: chemoport implantation will be done under local anesthesia using lidocaine.
Study NCT01733342 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: local anesthesia
Description: chemoport implantation will be done under local anesthesia using lidocaine.
Study NCT01733342 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Humanport chemoport implantation
Description: Humanport chemoport implantation was done under local anesthesia, at anterior chest wall, under ultrasound guidance
Study NCT02873650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabrafenib
Description: Single dose of 100 mg dabrafenib on Day 1
Study NCT02830672 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical release A1 pulley for Trigger finger of the hand
Study NCT05713773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: coated beads glucose (8 g) and caffeine anhydrous
Description: After an overnight fasting of about 10 hours the subjects were administered either glucose (8 g) or glucose (8 g) and caffeine starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position on Day 1.
Study NCT05713773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: coated beads glucose (8 g)
Description: After an overnight fasting of about 10 hours the subjects were administered glucose (8 g) starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position on Day 1.
Study NCT05713773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: uncoated beads glucose (8 g) and caffeine anhydrous
Description: After an overnight fasting of about 10 hours the subjects were administered either glucose (8 g) or glucose (8 g) and caffeine starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position on Day 1.
Study NCT00512746 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: cytology and cytometry specimen collection procedure
Description: Samples tested and further interventions added if positive
Study NCT00512746 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chest x ray
Description: Patients not diagnosed with lung cancer during the course of the study, will be offered an exit chest x-ray after 5 years or sooner if they withdraw from the trial before 5 years. This could help identify a lung cancer that may not have been associated with symptoms earlier.
Study NCT00512746 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Chest x ray
Description: Patients not diagnosed with lung cancer during the course of the study, will be offered an exit chest x-ray after 5 years or sooner if they withdraw from the trial before 5 years. This could help identify a lung cancer that may not have been associated with symptoms earlier.
Study NCT00512746 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Autofluorescence bronchoscopy
Description: The bronchial tree will be inspected first under white light and then under blue light. All areas that appear abnormal will initially be documented and only sampled when the bronchoscopic examination has been completed.
Study NCT00512746 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: CT scan
Description: All patients with abnormal sputum cytology and/or cytometry will undergo low dose spiral CT without contrast.
Study NCT01085552 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Epoetin Beta
Description: Epoetin Beta. A single subcutaneous dose of 50IU/kg on Day 1. The body weight recording on day -1 will be used to calculate the dosage
Study NCT00521924 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: infliximab
Description: infliximab 3 mg/kg and basic treatment
Study NCT00521924 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMARDs (methotrexate; chloroquine; leflunomidum; cyclosporin A; sulfasalazine; OM 89.
Description: Methotrexate (15 - 25 mg/week); chloroquine; leflunomidum; cyclosporin A; sulfasalazine; OM 89
Study NCT01454245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39439335
Description: Part 2:Type=2, unit=mg, number=12.5, form=capsule, route=oral use. Two capsules taken (25 mg/day) once on Day 1 in 2 treatment periods.
Study NCT01454245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39439335
Description: Part 1:Type=1, unit=mg, number=25, form=capsule, route=oral use. One capsule (25 mg/day) taken once on Day 1 in 3 treatment periods.~or Part 1:Type=2, unit=mg, number=12.5, form=capsule, route=oral use. Two capsules (25 mg/day) taken once on Day 1 in 3 treatment periods.
Study NCT02713035 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self help intervention
Description: For participants randomized to receive the treatment, the self-help intervention will be briefly described by a member of the clinical staff, and a brief pamphlet will be distributed to the parent or guardian at the end of the visit. The pamphlet describes behavioral strategies for coping with and reducing scratching behaviors. Participants randomly selected to not receive the treatment will not receive the pamphlet at the end of the visit.
Study NCT00141895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 2 tablets 200 micrograms Vaginal route
Study NCT00141895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 2 tablets of 200 micrograms Sublingual route
Study NCT03764163 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pulmonary Function Test
Description: Spirometry, Diffusing Capacity of the Lungs (DLCO), Lung Volumes
Study NCT03764163 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT Scans
Description: volume scans, perfusion scan, ventilation scan
Study NCT03764163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Human Subjects Questionnaire, Baseline Dyspnea Index, Chronic Respiratory Questionnaire
Study NCT03764163 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: proton scans, hyperpolarized 3-Helium scan
Study NCT03764163 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Xenon gas
Description: ventilation CT scans
Study NCT02615470 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced immunization delivery model
Description: Webinar and online training will be delivered to intervention pharmacist-technician pairs to discuss strategies that can be used to enhance immunization delivery model and how to integrate the new model into their routine practice. This intervention also includes feedback from immunization experts for the period of 6 months.
Study NCT02615470 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immunization update
Description: Basic immunization update online webinar will summarize changes in immunization schedules.
Study NCT02615470 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immunization update
Description: Basic immunization update online webinar will summarize changes in immunization schedules.
Study NCT02668653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Study NCT02668653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Study NCT00392353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC
Study NCT00392353 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00392353 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00392353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study NCT03971994 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Facial expression recognition task
Description: We will present emotional expressions to participants. Their task will be to determine which emotion is expressed by each face. Participants' eye movements and brain activity will be recorded while they explore the face.
Study NCT03971994 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facial expression recognition task
Description: We will present emotional expressions to participants. Their task will be to determine which emotion is expressed by each face. Participants' eye movements and brain activity will be recorded while they explore the face.
Study NCT02794454 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HeezOn Ultra-1
Study NCT02794454 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HeezOn Ultra-2
Study NCT02794454 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04047160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OP-724
Description: Twice a week for 4 hours continuous intravenous administration of OP-724
Study NCT03627767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842 100 mg
Description: PF-04965842 100 mg, administered as two tablets to be taken orally once daily for 40 weeks
Study NCT03627767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842 200 mg
Description: PF-04965842 200 mg, administered as two tablets to be taken orally once daily for 40 weeks
Study NCT03627767 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, administered as two tablets to be taken orally once daily for 40 weeks
Study NCT04472143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron Transdermal Delivery System
Description: A total of 60 patients with HER2-positive advanced breast cancer who are scheduled to receive pirotinib combined with capecitabine will be enrolled. A single transdermal patch will be applied to the subject' upper outer arm 24-48 hours before chemotherapy for 7 days. The observation period will be from the time of enrollment to 14 days (± 7 days) after the removal of granisetron patch.
Study NCT01717287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir Film-coated Tablet
Study NCT01717287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir Chewable Tablet
Study NCT01717287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Other Anti-Retroviral Therapy
Description: At baseline, the investigator selected the other anti-retroviral therapies to be used in combination with raltegravir based on current treatment guidelines, the participant's treatment history, and prior anti-retroviral resistance testing
Study NCT03561792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragm ultrasound
Description: In the semi-sitting position ultrasonography for diaphragmatic displacement was performed by the same intensivist. Diaphragmatic movement was evaluated by using 2 to 5 MHz US probe (Sonosite M-Turbo machine). The right hemidiaphragm was examined by two-dimensional (2D) and M-mode to record diaphragm displacement.in M-mode, the diaphragmatic displacement (cm) was measured and then DRSBI was calculated by respiratory rate (RR)/ diaphragmatic displacement (DD) (in mm)
Study NCT04414371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Yoga Namaskar and Nadi Shuddhi
Study NCT04414371 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Yoga
Description: Yoga Namaskar and Nadi Shuddhi
Study NCT03712436 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Palliative care
Description: The Palliative Care Package is a protocol for Palliative Care delivery, derived from the African Palliative Care Association and adapted to the local environment in Addis Ababa.
Study NCT03712436 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Standard oncological care
Description: Standard Oncological Care available in Addis Ababa, Ethiopia which includes chemotherapy, radiation oncology
Study NCT00947362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electro-thermo-coagulation
Study NCT00947362 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electro-thermo-coagulation
Study NCT00947362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAC N-055
Description: moist wound treatment plus 0.05 % pharmaceutical chlorite
Study NCT00947362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: physiological saline
Study NCT02744300 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BABI-2 Lifestyle Intervention
Description: Participants in this intervention will receive support from a lifestyle coach and gain access to a website with online presentations that contain healthy eating and physical activity educational tips.
Study NCT00453648 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: White-fleshed sweet potatoes
Study NCT00453648 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange-fleshed sweet potatoes (boiled)
Study NCT00453648 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange-fleshed sweet potatoes (fried)
Study NCT00453648 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WFSP and capsule of retinyl palmitate
Study NCT00930722 — intervention group
Intervention type: DRUG
Intervention: quinapril
Description: per label as non interventional study
Study NCT02963038 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CD19-targeting CAR T cells
Description: Autologous CD19-targeting CAR T cells with three signaling domains derived from CD3zeta, CD28 and 4-1BB.
Study NCT02801955 — intervention group
Intervention type: PROCEDURE
Intervention: gastrectomy
Description: radical total/subtotal gastrectomy with D2 lymph node dissection
Study NCT02801955 — intervention group
Intervention type: PROCEDURE
Intervention: sampling of peritoneal washing aspirate
Description: After thoroughly examination of the peritoneal cavity revealing the absence of peritoneal dissemination, the peritoneal cavity was washed with 200 ml of saline, and at least one third was aspirated from several regions of the peritoneal cavity, including near the primary tumor, the left and right subphrenic areas and the pouch of Douglas with suction tubes to a clean bottle and designated as the peritoneal sample for determination of peritoneal levels of CEA and CA 19-9.
Study NCT00295633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablets, Oral, 2.5 mg, Once daily (6 months ST, 12 months LT)
Study NCT00295633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablets, Oral, 5 mg, once daily (6 months ST, 12 months LT)
Study NCT00295633 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0 mg, Once daily (6 months ST, 12 months LT)